FBT

While the relentless spread of the coronavirus drove the equity market lower on Monday, there were also signs investors are preparing for a greater possibility that Democrats will gain control of the U.S. Senate.

Three big players have long made up the majority of the $5.4 trillion U.S. exchange-traded fund industry, but their latest offerings were also-rans in a record year for new product launches.

Chinese stocks listed in the U.S., including China Telecom Corp. and Pinduoduo Inc., fell on the prospect of further sanctions that would remove more of the Asian nation’s biggest companies from American stock exchanges.

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a

A broad and diverse effort is underway by biotech companies to solve the terrible riddle of the Coronavirus.Firms are forging ahead with testing, treatment and vaccine research and product development.Results of even the most promising treatments, however, are not yet clear cut. Even those that may be are not proof a bullish thesis for those companies that have developed them.Biotech investing is risky. The temptations of building a large position in a COVID 19-engaged public company are obvious.A wise investor would be well-served by opening or adding to such positions with a measure of caution.